|
|
Precigen Inc (NASDAQ: PGEN) |
|
Price: $1.5300
$0.11 
7.678%
|
| Day's High:
| $1.55
| Week Perf:
| 9.29 %
|
| Day's Low: |
$ 1.39 |
30 Day Perf: |
-15 % |
| Volume (M): |
1,981 |
52 Wk High: |
$ 2.17 |
| Volume (M$): |
$ 3,031 |
52 Wk Avg: |
$1.28 |
| Open: |
$1.39 |
52 Wk Low: |
$0.10 |
|
|
| Market Capitalization (Millions $) |
411 |
| Shares
Outstanding (Millions) |
269 |
| Employees |
99 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-126 |
| Cash Flow (TTM) (Millions $) |
22 |
| Capital Exp. (TTM) (Millions $) |
9 |
Precigen Inc
Precigen Inc is a biotechnology company that utilizes its proprietary technologies to develop innovative solutions in the field of genetic engineering and synthetic biology. The company focuses on several key areas including gene therapy, gene editing, and the creation of novel genetic medicines.
They have developed a platform called UltraVector, which enables the rapid and precise engineering of genes, allowing for the creation of customized genetic constructs. Precigen Inc also specializes in developing and commercializing gene therapies for the treatment of various diseases, including cancer, cardiovascular disorders, and rare genetic diseases.
Additionally, Precigen Inc is involved in the development of next-generation technologies like CRISPR-Cas9 gene editing, which has the potential to revolutionize the treatment of genetic disorders by allowing for precise modifications to be made to the genome.
The company collaborates with academic institutions, pharmaceutical companies, and government agencies to accelerate the development and commercialization of their genetic technologies. Their mission is to improve the lives of patients by providing innovative genetic solutions and personalized treatments.
Company Address: 20374 Seneca Meadows Parkway Germantown, 20876 MD
Company Phone Number: 556-9900 Stock Exchange / Ticker: NASDAQ PGEN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Precigen Inc
The Major Pharmaceutical Preparations company reported a disappointing financial performance for the January to March 31, 2024 period, with a significant decrease in revenue by -42.464% to $1.07 million. Precigen Inc, a subsidiary of the company, also recorded a shortfall in earnings per share, with a decrease to $-0.10 compared to the same period last year.
However, there were some improvements in comparison to the previous financial reporting period, with Income per Share showing improvement from $-0.13 per share and Revenue turning positive from $-4.92 million. Despite these improvements, Precigen Inc still realized a net shortfall of $-23.738 million for the January to March 31, 2024 period, which is larger than the shortfall of $-22.734 million reported a year ago.
|
| Precigen Inc
In the recently concluded earnings season, Precigen Inc (PGEN) reported a decline in earnings compared to the previous year, leading to an increased deficit per share. The company's financial results for the fourth quarter of 2023 show a net deficit of $33.056 million, which is significantly larger than the $22.176 million recorded in the same period a year ago. Furthermore, the company's accounts receivable have declined to $1.6 million, potentially indicating a slowdown in demand. This article will dive into the implications of these financial results and provide an analysis of Precigen Inc's performance.
1. Earnings per Share (EPS) Decrease:
Precigen Inc's EPS for the fourth quarter of 2023 amounted to -$0.13 per share, compared to -$0.11 per share in the previous year's quarter. This decline suggests that the company's financial performance has worsened over time. Moreover, in the preceding quarter, the company recorded an EPS of -$0.08, indicating a continued downward trend.
|
| Precigen Inc
Precigen Inc, a leading biotechnology company, recently released its financial results for the fiscal period ending on September 30, 2023. The results reveal a significant decline in revenue and a higher net loss per share compared to the same reporting period in the previous year. These findings paint a grim picture for the company's financial health and performance.
Financial Results:
1. Revenue Decrease: Precigen Inc experienced a staggering decline of -91.753% in revenue, dropping to $1.38 million for the fiscal period closing September 30, 2023. This marks a sharp fall from $1.77 million in the same reporting period a year earlier, representing a decline of -21.958%.
|
| Precigen Inc
In the second quarter of 2023, Precigen Inc (NASDAQ: PGEN) showcased a noteworthy improvement in its financial performance compared to the previous year. While the company recorded a decrease in revenue, significant strides were observed in terms of reducing losses per share and improving overall earnings.
Financial Performance:
During the second quarter of 2023, Precigen Inc reported a decrease in losses per share to $-0.08, a notable improvement from the $-0.09 recorded a year earlier. Furthermore, the company demonstrated enhanced earnings per share from the prior reporting period, with $-0.10 posted previously.
|
| Precigen Inc
Precigen Inc, a leading biotechnology company, released their financial report for the fiscal year ending March 31, 2023. The report shows that the company has incurred a loss of $0.10 per share, which is consistent with the previous year. Despite this, Precigen Inc's Income per Share has improved from $-0.11 in the previous financial period.
One significant drop in Precigen Inc's financial report is the sharp decrease in revenue. The company recorded a -94.219% decline in revenue, falling from $32.02 million to $1.85 million in the same financial reporting period a year ago. However, revenue has turned positive from $-24.75 million in the preceding quarter, suggesting that the company may be rebounding from their financial difficulties.
Furthermore, Precigen Inc realized a net loss of $-22.734 million for the fiscal year ending March 31, 2023, which is higher than the $-19.251 million loss in the previous year. This suggests that the company needs to improve their financial performance to remain competitive in the biotechnology sectorDespite these financial hurdles, Precigen Inc is expected to report its next financial earnings on August 07, 2023. With the economic climate rapidly changing, investors will keep a close watch on the company's performance over the next fiscal year to decide whether it is a suitable investment decision. Precigen Inc will need to make strategic moves to bounce back and generate profits in the coming months if they aim to secure their position in the biotechnology industry.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.49 $ |
| Revenues (TTM) |
0.01 $
|
| Cash Flow (TTM) |
0.08 $ |
| Cash |
0.36 $
|
| Book Value |
0.14 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.49 $
|
| Revenues (TTM) |
0.01 $ |
| Cash Flow (TTM) |
0.08 $ |
| Cash |
0.36 $
|
| Book Value |
0.14 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
2.4% 